Welcome to our dedicated page for Imac Hldgs news (Ticker: BACK), a resource for investors and traders seeking the latest updates and insights on Imac Hldgs stock.
News and filings for IMAC Holdings, Inc. (BACK) highlight a company pivoting toward precision oncology through its subsidiary Ignite Proteomics LLC. Recent announcements describe the launch of Ignite, the transfer of a key Proprietary Laboratory Analyses (PLA) code for a proteomic breast cancer assay, and multiple clinical and research collaborations that showcase how the company applies Reverse Phase Protein Array (RPPA) technology to guide cancer treatment decisions.
Investors and healthcare observers following BACK news will encounter updates on Ignite’s CLIA‑certified and CAP‑accredited laboratory operations, as well as data presentations and peer‑reviewed publications. These include a case study in npj Precision Oncology demonstrating a complete response in metastatic triple‑negative breast cancer guided by proteomic analysis, and a British Journal of Cancer paper on functional activation of the AKT–mTOR signaling axis as a predictor of therapy response.
Company news also covers collaborations with institutions such as Inova Health and Vanderbilt University Medical Center. These projects involve profiling tumor and immune‑signaling pathways in gastrointestinal and breast cancers, using RPPA‑based assays to generate biomarker data for molecular tumor boards and immuno‑oncology research teams. Additional releases discuss the completed transfer of PLA code 0249U to Ignite Proteomics, positioning the assay within the Medicare Clinical Laboratory Fee Schedule and MolDx guidance.
Alongside scientific and clinical milestones, the news flow for IMAC Holdings includes Nasdaq notifications related to delayed Form 10‑Q filings and extensions to regain compliance with listing rules. By reviewing this news stream, readers can see how IMAC combines regulatory developments, financing disclosures, and proteomics‑focused clinical progress as it advances its stated goal of improving patient outcomes and personalized cancer care.
IMAC Holdings (Nasdaq: BACK) announced the sale of The BackSpace to Curis Functional Health for an undisclosed amount. The BackSpace specializes in spinal health services within select Walmart locations. CEO Jeff Ervin expressed optimism regarding the transition, emphasizing a renewed focus on non-surgical medical care. Additionally, Dr. Ben Lerner, the Chief Operating Officer, has resigned, and the company will not appoint a replacement, as Dr. Matt Wallis will oversee operations. IMAC Holdings continues to manage rehabilitation services and is involved in clinical trials for innovative therapies.
IMAC Holdings, Inc. (BACK) reported strong financial results for Q3 2022 with total revenue increasing 9% to $3.78 million compared to $3.48 million in Q3 2021. The company achieved record visits of 1,818% growth at The BackSpace retail chiropractic centers. Notable achievements include completing a $3.9 million funding round and concluding the Phase 1 clinical study for Parkinson's treatment. The company reduced liabilities by $1 million and introduced new medical services aimed at driving future revenues.
IMAC Holdings (Nasdaq: BACK) has launched an e-commerce platform to retail its Vita Eternum organic supplement line. The products, which include ashwagandha, multivitamins, and collagen protein, are priced between $29 and $49. CEO Jeff Ervin stated that this initiative aligns with the health interests of IMAC's patients and expands the company's market reach via online sales. The U.S. vitamin and supplement market is projected to generate $37.2 billion in sales in 2022. IMAC Holdings focuses on health and wellness through outpatient centers and clinical research.
IMAC Holdings has partnered with Evoke Chiropractic Coaching to promote its new organic, whole food supplements to physician offices. The collaboration kicks off with a panel discussion featuring notable athletes at the Evoke 3rd Annual Conference in St. Louis. The event aims to educate attendees on health, diet, and supplementation while supporting Evoke's mission to assist minority chiropractors. IMAC's COO, Dr. Ben Lerner, stated this initiative will help improve community health through their supplement line.
IMAC Holdings, Inc. (NASDAQ: BACK) announced the completion of the third cohort in its Phase 1 clinical trial of an investigational compound using umbilical cord-derived allogenic mesenchymal stem cells targeting bradykinesia due to Parkinson’s disease. This cohort included five patients receiving a high concentration stem cell treatment. The trial, conducted in three clinical centers, involved 15 patients across different dosage groups. The safety and tolerability study is set to track participants for 12 months, with potential implications for the growing Parkinson’s therapeutics market, projected to reach $5.28 billion by 2025.
IMAC Holdings has partnered with Biote to incorporate Biote's hormone optimization services into IMAC outpatient clinics. This collaboration aims to enhance patient care in weight loss and hormone therapy, addressing obesity and related chronic illnesses. IMAC will begin training its medical staff in the Biote Method in September. Both companies express optimism regarding their joint ability to improve health outcomes for patients across various age groups. This strategic partnership aligns with their missions to provide advanced health solutions.
Biote Corp. (Nasdaq: BTMD) has partnered with IMAC Holdings (Nasdaq: BACK) to introduce Biote's hormone optimization services in IMAC's outpatient clinics. This collaboration aims to enhance patient care by integrating innovative treatments for obesity and chronic pain. Training for IMAC professionals on the Biote Method is set to begin in September. Biote specializes in building medical practices focused on hormone optimization, while IMAC provides regenerative rehabilitation for musculoskeletal and neurological conditions.
IMAC Holdings (Nasdaq: BACK) has launched medical weight loss services at its IMAC Regeneration Centers in three locations. This initiative aims to enhance patient rehabilitation and attract new clients to its orthopedic services. CEO Jeffrey Ervin emphasized the link between obesity and chronic back pain, stating that the weight loss program will be customized for individuals and cost between $1,500 to $4,000 annually. The American Journal of Preventative Medicine predicts that 42% of US adults may be obese by 2030, highlighting the growing relevance of this service.
IMAC Holdings, Inc. (Nasdaq: BACK) has successfully closed a registered direct offering and private placement, raising approximately $3.9 million by issuing 5,164,474 shares at $0.76 per share. Each investor received Series 1 and Series 2 warrants for the same number of shares, with an exercise price of $0.95 per share. The net proceeds will be used for working capital and strategic initiatives. Joseph Gunnar & Co., LLC served as the sole placement agent for the transaction.
IMAC Holdings reported strong preliminary financial results for Q2 2022 with total revenue reaching $5.0 million, a 45% increase from Q2 2021's $3.5 million. Despite a 5.1% decline in patient visits to 42,495, the company saw significant growth in The BackSpace clinics with a 207% sequential increase, aided by plans to expand to at least 20 additional Walmart locations. The company has also launched a certified organic vitamin line and successfully amended its NASDAQ trading symbol from IMAC to BACK. Financial stability was bolstered by a $3.9 million direct offering.